Transcode Therapeutics Inc
Change company Symbol lookup
Select an option...
RNAZ Transcode Therapeutics Inc
PNC PNC Financial Services Group Inc
BMDPF Banca Monte dei Paschi di Siena SpA
CACH Cache Inc
EPIX ESSA Pharma Inc
PRIF-G Priority Income Fund Inc
BAC Bank of America Corp
TMBXF Tombstone Exploration Corp
TZPS TZP Strategies Acquisition Corp
HUM Humana Inc
Go

Health Care : Biotechnology |
Company profile

TransCode Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for treating metastatic disease. The Company’s development pipeline includes TTX-MC138, TTX-siPD-L1 and TTX-RIGA, TTX-siLIN28B, and TCD-miR10b. The Company has developed a modular, iron oxide nanoparticle-based nanocarrier system for the delivery of RNA therapeutics to tumors. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include two solid tumor programs such as TTX-siPDL1, a small interfering RNA (siRNA)based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLin28b, a siRNA-based inhibitor of RNA-binding protein LIN28B. Its TTX platform is modular by design, both at the level of the core nanoparticle and at the therapeutic loading.

Closing Price
$2.01
Day's Change
-0.08 (-3.83%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.16
Day's Low
2.00
Volume
(Light)
Volume:
6,629

10-day average volume:
28,648
6,629

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.